AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1. (cancelled)
- 2. (currently amended) A compound in accordance with claim 1 of formula (Ia)

$$X_1$$
 X_2
(I a)

(where wherein:

 X_1 and X_2 represent independently represents a hydrogen atom or, and X_2 represents a group of formula (II)

 $\underline{X_1}$ represents a group of formula (II), and $\underline{X_2}$ represents a hydrogen atom;

in which:

R₁ represents a linear or branched halogenoalkyl group having 1-7 carbon atoms nonafluoro-n-butyl group;

m is an integer of 2-14_8; and

n is an integer of 2-7_3; or

provided that X_{\perp} and X_{2} are not both a hydrogen atom), stereoisomers of the compound, or hydrates, salts or esters thereof.

3. (currently amended) A compound in accordance with claim 1 of formula (Ib)

$$X_1$$
 X_2 X_2 X_3 X_4 X_4 X_5 X_5 X_6 X_6 X_6 X_7 X_8

(wherewherein:

 X_1 and X_2 represent independently represents a hydrogen atom, and X_2 represents or a group of formula (II)

$$COOH$$
 — $(CH_2)_m$ — CH — $(CH_2)_n$ R₁ (II) _ ; or

 $\underline{X_1}$ represents a group of formula (II), and $\underline{X_2}$ represents a hydrogen atom;

in which:

R₁ represents a linear or branched halogenoalkyl group having 1-7 carbon atoms nonafluoro-n-butyl group;

Rb represents a linear or branched alkynylan ethynyl group having 2-5 carbon atoms;

m is an integer of 2-14_8; and

n isan integer of 2-7_3;or

provided that X_{\pm} and X_{2} are not both a hydrogen atom),

stereoisomers of the compound, or hydrates, salts or esters thereof.

4-5. (cancelled)

6. (currently amended) A pharmaceutical composition

comprising the compound, stereoisomers of the compound, $\frac{1}{2}$ hydrates, salts or esters thereof according to claim $\frac{1}{2}$ as an active ingredient, together with a pharmaceutically acceptable excipient.

- 7. (previously presented) The pharmaceutical composition according to claim 6 formulated for use to prevent or treat osteoporosis.
- 8. (previously presented) The pharmaceutical composition according to claim 6 formulated for use to prevent or treat breast cancer.
- 9. (currently amended) A process for producing a compound of formula (Ia)

$$X_1$$
 X_2
(I a)

(wherewherein:

in which:

 X_1 and X_2 represent independently represents a hydrogen atom, and X_2 represents or a group of formula (II)

$$COOH$$
 $-(CH_2)_m$ $-(CH_2)_n$ R_1 CH_2 CH_2 CH_3 CH_4 CH_4 CH_5 CH_5

 $\underline{X_1}$ represents a group of formula (II), and $\underline{X_2}$ represents a hydrogen atom;

 R_1 represents a linear or branched halogenealkyl

group having 1-7 carbon atoms nonafluoro-n-butyl group;

m is—an integer of 2-14_8;

n is an integer of 2-7_3; or

provided that X₊ and X₂ are not both a hydrogen atom),

stereoisomers of the compound, or hydrates, salts or esters thereof, said process including the step of:

oxidizing a compound of formula (III)

$$X_1$$
 X_2 (III)

(where X_1 and X_2 represent independently a hydrogen atom or a group of formula (II)

R₊ represents a linear or branched halogenoalkyl group having 1-7 carbon atoms;

m is an integer of 2-14;

n is an integer of 2-7;

provided that X_1 and X_2 are not both a hydrogen atom), wherein X_1 and X_2 are defined as above, or stereoisomers of the compound, or hydrates, salts or esters thereof.

10. (original) The process according to claim 9, in which the oxidation reaction is performed by Oppenauer

oxidation.

11. (currently amended) A process for producing a
compound of formula (Ib)

$$X_1$$
 X_2 X_2 X_3 X_4 X_4 X_5 X_5 X_6 X_6 X_6 X_7 X_8

(wherewherein:

 X_1 and X_2 represent independently represents a hydrogen atom, or and X_2 represents a group of formula (II)

COOH —
$$(CH_2)_m$$
— CH — $(CH_2)_n$ R₁ (II) ; or

 $\underline{X_1}$ represents a group of formula (II), and $\underline{X_2}$ represents a hydrogen atom;

in which:

 R_1 represents a linear or branched halogenoalkyl group having 1-7 carbon atoms nonafluoro-n-butyl group;

Rb represents a linear or branched alkynyl ethynyl group having 2-5 carbon atoms;

m is an integer of 2-14 8; and

n is an integer of $2-7_3$; or

provided that X_{\pm} and X_{2} are not both a hydrogen atom),

stereoisomers of the compound, or hydrates, salts or esters thereof, said process including the step of:

alkynylating a compound of formula (Ia)

$$X_1$$
 X_2
 (Ia)

(where wherein:

 X_1 and X_2 are defined as above; or represent independently a hydrogen atom or a group of formula (II)

$$\frac{\text{COOH}}{\text{--(CH}_2)_m\text{--CH}\text{--(CH}_2)_nR_1}$$

R₊ represents a linear or branched halogenoalkyl group having 1-7 carbon atoms;

m is an integer of 2-14;

n is an integer of 2-7;

provided that X₁ and X₂ are not both a hydrogen atom),

stereoisomers of the compound, or hydrates, salts or esters thereof.

- 12. (new) A pharmaceutical composition comprising the compound, stereoisomers of the compound, salts or esters thereof according to claim 3 as an active ingredient.
- 13. (new) The pharmaceutical composition according to claim 12 which is used to prevent or treat osteoporosis.
- 14. (new) The pharmaceutical composition according to claim 12 which is used to prevent or treat breast cancer.